On this show, I'm delighted to sit down in conversation with Lifespin CEO Dr Ali Tinazli based in Germany, to record a video podcastfor the Domus Search Leadership Podcast.
Domus Search is committed to sharing leadership insight to our network. The podcast offers a glimpse into the world of industry leaders through interactive conversations with CEO's, C-Suite Executives and Executive Leadership Teams across European BioPharma and MedTech sectors.
About my guest.
Dr Ali Tinazli completed his MSc in Biochemistry, Biophysics and Molecular Biology and went on to achieve his PhD in Nanotechnology from Goethe University, Germany. He went on to complete Executive Education with Massachusetts Institute of Technology, MIT Professional Education and Univesity of California, Berkeley, Haas School of Business.
Since completing his PhD, Ali has gone on to take leadership roles in many household names such as Sony and HP, where he led the global strategy governing the company’s initiatives in Healthcare and Life Sciences, with a focus on Point of Care and Digital Health
Ali sits on the Board of Softhread, a a blockchain and AI-enabled platform to build enterprise solutions and Fluxergy, a Point of Care Health Diagnostic Solutions based in California. He is also a member of the Forbes Technology Council
As CEO of lLifespin, amongst many other responsibilities, Ali is charged with the leadership and growth of Lifespin into new regions, developing strategic partnerships and putting Lifespin on the map. His global expertise and subject matter expertise positions Ali at the intersection of consumer technologies and healthcare, commercialising technology in Life Sciences and in vitro diagnostics.
About Lifespin.
The Lifespin platform combines biology, deep data, artificial intelligence and cloud technologies to enable digital metabolic insights for Precision diagnostics, Personalised Disease management, Precision Drug Monitoring for Pharma, Research and much more.
Lifespin is building a proprietary database, already consisting of more than 150k individual human metabolic profiles, to create a digital atlas of human health that provides deeper clinical insights based on metabolic information.
The first commercial product in the regulated space will be software algorithms for health testing this year as a laboratory-developed test for clinical evaluation of Multiple Sclerosis followed by a test for Parkinson’s Disease diagnosis in 2023. The clinical findings to date using lifespin’s technology platform in a research-use-only context are highly promising.
Connect with Dr Ali.
https://lifespin.health
https://www.linkedin.com/in/dralitinazli/
Keep in touch with Lifespin & Dr Ali at industry events
https://lifespin.health/newsroom/